K van der Zwaluw1, S Witteveen2, L Wielders2, M van Santen2, F Landman2, A de Haan2, L M Schouls2, T Bosch2. 1. Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. Electronic address: Kim.van.der.Zwaluw@rivm.nl. 2. Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Abstract
OBJECTIVES: Carbapenem resistance mediated by mobile genetic elements has emerged worldwide and has become a major public health threat. To gain insight into the molecular epidemiology of carbapenem resistance in The Netherlands, Dutch medical microbiology laboratories are requested to submit suspected carbapenemase-producing Enterobacterales (CPE) to the National Institute for Public Health and the Environment as part of a national surveillance system. METHODS: Meropenem MICs and species identification were confirmed by E-test and MALDI-TOF and carbapenemase production was assessed by the Carbapenem Inactivation Method. Of all submitted CPE, one species/carbapenemase gene combination per person per year was subjected to next-generation sequencing (NGS). RESULTS: In total, 1838 unique isolates were received between 2014 and 2018, of which 892 were unique CPE isolates with NGS data available. The predominant CPE species were Klebsiella pneumoniae (n = 388, 43%), Escherichia coli (n = 264, 30%) and Enterobacter cloacae complex (n = 116, 13%). Various carbapenemase alleles of the same carbapenemase gene resulted in different susceptibilities to meropenem and this effect varied between species. Analyses of NGS data showed variation of prevalence of carbapenemase alleles over time with blaOXA-48 being predominant (38%, 336/892), followed by blaNDM-1 (16%, 145/892). For the first time in the Netherlands, blaOXA-181, blaOXA-232 and blaVIM-4 were detected. The genetic background of K. pneumoniae and E. coli isolates was highly diverse. CONCLUSIONS: The CPE population in the Netherlands is diverse, suggesting multiple introductions. The predominant carbapenemase alleles are blaOXA-48 and blaNDM-1. There was a clear association between species, carbapenemase allele and susceptibility to meropenem.
OBJECTIVES:Carbapenem resistance mediated by mobile genetic elements has emerged worldwide and has become a major public health threat. To gain insight into the molecular epidemiology of carbapenem resistance in The Netherlands, Dutch medical microbiology laboratories are requested to submit suspected carbapenemase-producing Enterobacterales (CPE) to the National Institute for Public Health and the Environment as part of a national surveillance system. METHODS:Meropenem MICs and species identification were confirmed by E-test and MALDI-TOF and carbapenemase production was assessed by the Carbapenem Inactivation Method. Of all submitted CPE, one species/carbapenemase gene combination per person per year was subjected to next-generation sequencing (NGS). RESULTS: In total, 1838 unique isolates were received between 2014 and 2018, of which 892 were unique CPE isolates with NGS data available. The predominant CPE species were Klebsiella pneumoniae (n = 388, 43%), Escherichia coli (n = 264, 30%) and Enterobacter cloacae complex (n = 116, 13%). Various carbapenemase alleles of the same carbapenemase gene resulted in different susceptibilities to meropenem and this effect varied between species. Analyses of NGS data showed variation of prevalence of carbapenemase alleles over time with blaOXA-48 being predominant (38%, 336/892), followed by blaNDM-1 (16%, 145/892). For the first time in the Netherlands, blaOXA-181, blaOXA-232 and blaVIM-4 were detected. The genetic background of K. pneumoniae and E. coli isolates was highly diverse. CONCLUSIONS: The CPE population in the Netherlands is diverse, suggesting multiple introductions. The predominant carbapenemase alleles are blaOXA-48 and blaNDM-1. There was a clear association between species, carbapenemase allele and susceptibility to meropenem.
Authors: Karuna E W Vendrik; Angela de Haan; Sandra Witteveen; Antoni P A Hendrickx; Fabian Landman; Daan W Notermans; Paul Bijkerk; Annelot F Schoffelen; Sabine C de Greeff; Cornelia C H Wielders; Jelle J Goeman; Ed J Kuijper; Leo M Schouls Journal: Commun Med (Lond) Date: 2022-05-20
Authors: Antoni P A Hendrickx; Fabian Landman; Angela de Haan; Dyogo Borst; Sandra Witteveen; Marga G van Santen-Verheuvel; Han G J van der Heide; Leo M Schouls Journal: Sci Rep Date: 2020-10-08 Impact factor: 4.379
Authors: Cornelia C H Wielders; Leo M Schouls; Sjoukje H S Woudt; Daan W Notermans; Antoni P A Hendrickx; Jacinta Bakker; Ed J Kuijper; Annelot F Schoffelen; Sabine C de Greeff Journal: Antimicrob Resist Infect Control Date: 2022-04-09 Impact factor: 4.887
Authors: Antoni P A Hendrickx; Sylvia Debast; María Pérez-Vázquez; Annelot F Schoffelen; Daan W Notermans; Fabian Landman; Cornelia C H Wielders; Javier E Cañada Garcia; Jacky Flipse; Angela de Haan; Sandra Witteveen; Marga van Santen-Verheuvel; Sabine C de Greeff; Ed Kuijper; Leo M Schouls Journal: JAC Antimicrob Resist Date: 2021-05-12
Authors: Jannette Pirzadian; Marjolein C Persoon; Juliëtte A Severin; Corné H W Klaassen; Sabine C de Greeff; Marcel G Mennen; Annelot F Schoffelen; Cornelia C H Wielders; Sandra Witteveen; Marga van Santen-Verheuvel; Leo M Schouls; Margreet C Vos Journal: Sci Rep Date: 2021-10-25 Impact factor: 4.379